Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools
Proteintech, the benchmark in antibodies, today announces the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies.
ChromoTek is the market leader in nanobodies — high-performance recombinant reagents used for breakthrough research discoveries. The combined companies will better address the industry’s growing opportunities and challenges in single cell analysis, super resolution imaging, and multiplex assays.
“Our fit-for-purpose nanobody-based tools perfectly complement the comprehensive antibody coverage of the proteome that Proteintech offers,” said Dr. Marion Jung, CEO of ChromoTek. “It is exciting to be working together with a company that shares our common values in reproducibility and quality for the benefit of research and beyond.”
Dr. Jason Li, CEO of Proteintech said, “This new partnership will deliver considerable value to the market. With global manufacturing across three continents, not only will we serve the research market better, but we’ll also deeply impact translational science and therapeutic applications.”
About Proteintech Group
Proteintech, founded in 2002, is a leading manufacturer of antibodies, proteins and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. With over 70,000 publications and confirmed specificity, Proteintech offers antibodies and immunoassays across research areas. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001-2015 accredited. To learn more about Proteintech, please visit www.ptglab.com .
ChromoTek is a pioneer in the development and commercialization of innovative reagents based on camelid Nanobodies. In contrast to traditional antibodies, Nanobodies consist of only one single polypeptide chain; they are the smallest known antibodies. The company has a unique experience in the development of Nanobodies with desired affinities, specificities, and formats for dedicated applications in biomedical research where other antibody formats fail. As a market and product leader for high performing reagents, we are proud contributing to breakthrough research discoveries around the world. In addition, ChromoTek is a trusted service provider of custom-made Nanobodies for the pharmaceutical industry. Founded in 2008, ChromoTek has offices in Martinsried (Germany) near Munich and Islandia (NY, USA).
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
YOKOGAWA-ELECTRIC2.12.2021 03:02:06 CET | Press release
Yokogawa Acquires PXiSE, a Developer of High-speed Control Software for Grids and Renewable Energy Assets
APPLIED-RISK2.12.2021 01:02:35 CET | Press release
Applied Risk releases new Operational Technology (OT) Security report, “Architecting the Next Generation for OT Security”
SEOUL-SEMICONDUCTOR2.12.2021 01:02:05 CET | Press release
Seoul Semiconductor Supplies SunLike LED, a Natural Light Reproduction Technology, to KOIZUMI's Learning Lighting
CA-HUMANIGEN,-INC.2.12.2021 00:32:13 CET | Press release
The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
CA-BLOCK,-INC.1.12.2021 22:32:12 CET | Press release
Square, Inc. Changes Name to Block
PA-BENTLEY-SYSTEMS1.12.2021 22:03:10 CET | Press release
Bentley Systems Announces the Year in Infrastructure 2021 Founders’ Honorees
ESI/APAVE/ONET1.12.2021 18:30:04 CET | Press release
CORRECTING and REPLACING: Apave, ESI Group and Onet Technologies – A unique alliance for an outstanding EPR project at the Jaitapur site in India
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom